Outcomes16

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 16 of 16

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.	16 weeks		score on a scale	MEDIAN
SECONDARY	The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks.	32 weeks		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.	16 weeks		score on a scale	MEDIAN
SECONDARY	The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints.	16 weeks		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	The Change in Levels of High Sensitivity C-reactive Protein From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.	16 weeks		µg/ml	MEDIAN
SECONDARY	The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Serum Cytokine Tumour Necrosis Factor Alpha.	16 weeks		pg/ml	MEDIAN
SECONDARY	The Change in PASI From Baseline to 32 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.	baseline and 32 weeks	The change in PASI at 32 weeks	score on a scale	MEDIAN
SECONDARY	The Change in Weight From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.	16 weeks		kg	MEDIAN
OTHER_PRE_SPECIFIED	The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Interleukin-17 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).	16 weeks	Skin cytokine endpoints	dCt	MEDIAN
SECONDARY	The Change in Levels of Systolic Blood Pressure From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.	16 weeks		mmHg	MEDIAN
SECONDARY	The Change in Levels of Serum Glucose From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.	16 weeks		mmol/L	MEDIAN
SECONDARY	The Change in Levels of Total Cholesterol From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.	16 weeks		mmol/L	MEDIAN
SECONDARY	The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-23.	16 weeks		pg/ml	MEDIAN
SECONDARY	The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-17.	16 weeks		pg/ml	MEDIAN
SECONDARY	The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.	16 weeks		pg/ml	MEDIAN
OTHER_PRE_SPECIFIED	The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).	16 weeks	Skin cytokine endpoints	dCt	MEDIAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01991197/outcomes

API reference For AI assistants